Elevar Therapeutics, Inc., a majority-owned subsidiary of HLB Co., Ltd. and a fully integrated biopharmaceutical company dedicated to  levating treatment experiences and outcomes for patients who have limited or inadequate therapeutic options, today announced its articipation plans for the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago and the 2023 BIO International Convention in Boston.

Please refer to the following website for further details: Elevar Therapeutics to Participate in ASCO 2023 and BIO 2023; New Jersey-based Company Secures State License as It Builds Toward - Bloomberg